Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Using the Swedish and Danish Lymphoma Registries from 2000 to 2011––which included over 95% of all diagnosed lymphoma patients in Sweden and Denmark––the study authors obtained novel data about the prognostic factors and primary treatment of mantle-cell lymphoma (MCL).
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Oral arsenic trioxide (ATO) was originally developed for the treatment of relapsed acute promyelocytic leukemia. In this study, Gill and colleagues investigated the use of an oral ATO-based regimen for patients with relapsed or refractory mantle-cell lymphoma (MCL).
The Single-Agent BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed In All Mantle-Cell Lymphoma Patients
Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation Prolongs Progression- Free Survival in Patients with Mantle-Cell Lymphoma
The RiBVD Regimen Offers a High Complete Response Rate in Elderly Patients with Untreated Mantle- Cell Lymphoma. Preliminary Results of the LYSA Trial “Lymphome Du Manteau 2010 SA”
Supported by the French LYSA (Lymphome Du Manteau 2010 SA) group, this prospective phase 2 trial evaluated the efficacy and safety of a 4-drug combination known as RiBVD (rituximab, bendamustine, bortezomib, and dexamethasone) in elderly patients with previously untreated mantle- cell lymphoma (MCL), including patients older than 65 years or patients who were not eligible for autologous stem-cell transplantation.
Lenalidomide, Bendamustine, and Rituximab as First-Line Therapy for Patients >65 Years with Mantle-Cell Lymphoma: Preliminary Results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase 1-2 Trial
Mantle-cell lymphoma (MCL) is a disease of the elderly; the median age at diagnosis is 70 years. Currently, the standard therapy for elderly patients has not been defined. In this trial, Jerkeman and colleagues investigated whether the addition of lenalidomide (LEN) to bendamustine plus rituximab (BR) followed by LEN maintenance for 7 months would improve the efficacy and safety of treatment among older patients with MCL.
Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab
During the 2013 Annual Meeting of the American Society of Hematology, Michael E Williams, MD, chaired an educational session titled, “Transplant for Mantle-Cell Lymphoma: Is it the Right Thing to Do?”, in which he presented clinical progress and current challenges in the treatment of patients with mantle-cell lymphoma (MCL).
Page 1 of 4
Results 1 - 10 of 37
Results 1 - 10 of 37